Thursday, June 5, 2014
Hyatt Regency San Francisco
Regenerative Medicine and Cellular Therapy

All education session events will take place in the Grand Ballroom.

8:00am – 8:10am Introduction
Joanne Kurtzberg, MD, Duke University Medical Center

8:10am – 9:50am
Session IA: How Are Stem Cells Marching to the Clinic?
Moderator – Andrew Balber, PhD, Duke University

The View From Academia
Mahendra Rao, MD, PhD, National Institute of Health

The View From Industry
Edward Field, MBA, Cytomedix, Inc.

Advancing Stem Cell Science Towards Therapies for Patients: CIRM’s Experience and Future Directions
Ellen Feigal, MD, CIRM

9:50am – 10:10am Coffee Break – Pacific Concourse

10:10am – 12:30pm
Session IB: Cellular Therapies for Neurological Diseases, Treatments Near or In the Clinic Today
Moderator – TBD

Therapeutic Use of Oligodendrocyte Progenitor Cells for Brain Remyelination
Martha Windrem, MD, University of Rochester

Autologous Cord Blood Shows Promise in the Treatment of HIE
Michael Cotton, MD, Duke University Medical Center

Utilization of Multiple Autologous Cord Blood Infusions to Treat Children With Brain Injury
Joanne Kurtzberg, MD, Duke University Medical Center

A Randomized Trial of Autologous Bone Marrow vs. Cord Blood in Children with CP
Charles S. Cox, Jr., MD, University of Texas – Houston Medical School

Cord Blood to Treat CP in Children: What are the Pathways to Allogeneic Cell Therapies?
Joanne Kurtzberg, MD, Duke University Medical Center

12:30pm – 1:30pm Lunch – Pacific Concourse
1:30pm – 3:30pm

**Session IIA:** Derivative Products from CORD Blood and Placental Tissue

**Moderator** - Jennifer Willert, MD, Stanford University

Development of More Than Minimally Manipulated Cord Blood Products: Pathways for Academic Development
Colleen Delaney, MD, Fred Hutchinson Cancer Research Center

The Potential for Cord Blood Derived MSC in RM: Manufacturing and Clinical Issues
Morey Kraus, PhD, ViaCord

Preclinical Evidence That Cord Blood Derived Endothelial Colony Forming Cells Display Potential as Vasculo-Reparative Agents
Mervin C. Yoder, MD, University of Indiana

New Horizons for the Ex Vivo Modulation of Cord Blood
Daniel Shoemaker, PhD, Fate Therapeutics

3:30pm – 3:50pm
Coffee Break – Pacific Concourse

3:50pm – 5:10pm

**Session IIB:** Challenges and Opportunities for Resourcing, Financing and Regulating Development and Clinical Use of Cord Blood Products in Regenerative Medicine

**Moderator** - Joanne Kurtzberg, MD, Duke University Medical Center

Current Costs of Blood Transplants: Impact of Licensure on Cord Blood Transplants, Implications for the Use of CB in RM
Michael Boo, JD, NMDP

Regulatory Challenges to Bringing Cord Blood Derived Products to the Clinic
Mercy Quagraine, PhD, FDA

Innovative Financing and Insurance of Cord Blood Banking for Better Future Use of Cord Blood Units in Regenerative Medicine
Arie Giniger, PhD, Irsael

5:10 pm – 5:30pm
Discussion & Closing Comments

5:30 pm – 7:30pm
Welcome and Abstract Poster Reception, Grand Ballroom Foyer and Market Street Foyer
Friday, June 6, 2014
CLINICAL TRANSPLANTATION AND CORD BLOOD BANKING

8:00am – 9:30am
SESSIONS IIIA: The Necessity and Urgency of Encouraging Appropriate Utilization of Cord Blood Transplantation
Moderators– Joseph Alvarnas, MD, City of Hope & Vanderson Rocha, MD, PhD, Eurocord and Oxford University

8:00am – 8:30am
The Problem of Absent or Late Referrals by Hematologists and Efforts Toward Improvement
Joseph Alvarnas, MD, City of Hope

8:30am – 8:50am
Expanding the Indications of Cord Blood Transplantation: HCT for Patients with Hematologic Malignancies in the Sixth to Eighth Decades of Life
Amanda Olson, MD, MD Anderson Cancer Center

8:50am – 9:10am
Expanding the Indications for Cord Blood Transplantation: New Cohorts Who Might Likely Benefit
Daniel Weisdorf, MD, University of Minnesota

9:10am – 9:30am
Unrelated Cord Blood Transplantation has Outcomes Comparable to Similar Patient Groups Treated with Matched Unrelated Donor Transplants.
Annalisa Ruggeri, MD, Eurocord International Registry

9:30am – 9:50am Coffee Break – Pacific Concourse

9:50am – 12:00pm
Session IIIIB: The Necessity and Urgency of Encouraging Appropriate Utilization of Cord Blood Transplantation (cont)
Moderators– Joseph Alvarnas, MD, City of Hope & Vanderson Rocha, MD, PhD, Eurocord and Oxford University

9:50am – 10:20am
Comparative Outcomes After RIC UCBT vs. RIC 8/8 PB in Adults with Lymphoid Malignancies
Vanderson Rocha, MD, PhD, Eurocord and Oxford University

10:20am – 10:40am
Transplantation for All Patients Including Those of Racial and Ethnical Minorities: Improved Allograft Access with Enlarging CB Inventory
Parastoo B. Dahi, MD, Memorial Sloan-Kettering Cancer Center

10:40am – 11:00am
Chronic GVHD Burden is Lower Following Adult Cord Blood Versus MURD Transplant
Jonathan Gutman, MD, University of Colorado
11:00am – 11:20 am
Alternative Donors Extend Transplantation for Patients With Lymphoma Who Lack an HLA Matched Donor
Veronika Bachnova, MD, University of Minnesota

11:20am – 12:00pm
Discussion of SESSIONS IIIA and IIIB

12:00pm -1:00pm Lunch– Pacific Concourse

1:00pm – 3:00pm
**Session IV:** What is the Optimal Means of Providing Adequate Cell Does in Cord Blood Transplantation? Discussion and Debate
**Moderator**– Claudio Brunstein, MD, University of Minnesota

1:00pm – 1:20pm
Double Cord Blood HCT
Juliet Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center

1:20pm – 1:40pm
Cell Expansion
Colleen Delaney, MD, Fred Hutchinson Cancer Research Center

1:40pm – 2:00pm
Dual Haplo/CB HCTs
Koen Van Besien, PhD, NYP-Weill Cornell College of Medicine

2:00pm – 2:20pm
Haploidentical Hematopoietic Cell Transplantation.
Richard Champlin, MD, MD Anderson Cancer Center

2:20pm – 3:00 pm
Discussion and Debate

3:00pm – 3:20pm Coffee Break – Pacific Concourse

3:20pm – 5:00pm
**Session IV:** The Selection of Optimal Donors for CB HCT
**Moderators** – Mary Eapen, MD, Medical College of Wisconsin & Sarah Cooley, MD, University of Minnesota

3:20pm – 3:40pm
Toward Eliminating HLA Class I Expression to Generate Universal Cells From Allogeneic Donors
Hiroki Troikai, MD, MD Anderson Cancer Center
3:40pm – 4:00pm
The Significance of Allele-Level HLA-Matching after Myeloablative Single CB Transplantation for Hematologic Malginy
Mary Eapen, MD, Medical College of Wisconsin

4:00pm – 4:20pm
Killer Cell Immunoglobulin-like receptor (KIR) Typing to Select Donors with Potential Natural Killer (NK) Alloreactivity
Sarah Cooley, MD, University of Minnesota

4:20pm – 4:40pm
Outcomes of Patients with Hemoglobinopathies Given Either CB or BM HCT from an HLA-identical Sibling
Mark Walters, MD, Children’s Hospital and Research Center of Oakland

4:40pm – 5:00pm Discussion

5:30pm – 6:30pm Cytolon Industry Workshop, Bayview B Room

6:30 pm – 8:30 pm MNX Reception, Atrium
Saturday, June 7, 2014
Cord Blood Banking & Clinical Advancements

8:00am – 9:40am
**Session VI:** New Findings Regarding GVHD, Minimal Residual Disease and the Use of ATG
Moderators – Doris Ponce, MD, Memorial Sloan-Kettering Cancer Center; Michael Pulsipher, MD, University of Utah

8:00am – 8:30am
The Prevention and Management of GVHD
Doris Ponce, MD, Memorial Sloan-Kettering Cancer Center

8:30am – 8:45am
The Role of Regulatory: T cells in Preventing GVHD
Claudio Brunstein, MD, University of Minnesota

8:45am – 9:00am
Striking Predictive Power for Relapse and Decreased Survival with Detectable Minimal Residual Disease
Michael Pulsipher, MD, University of Utah

9:00am – 9:15am
Quantitative Assessment of T cell Repertoire Recovery After Umbilical Cord Blood Transplantation Using Next Generation Sequencing
Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center

9:15am – 9:30am
Facilitating Engraftment in Patients at High Risk for Graft Rejection Following Reduced Intensity Conditioning: An Alternative to ATG
Rachel Salit, MD, Fred Hutchinson Cancer Research Center

9:30am – 9:40am  Discussant: Vanderson Rocha, MD, PhD

9:40am – 10:00am  Coffee Break – Pacific Concourse

10:00am – 12:00pm
**Session VII:** Means to Enhance Engraftment of Cord Blood Cells
Moderators - Elizabeth Shpall, MD, MD Anderson Cancer Center & Mitchell Horwitz, MD, Duke University Medical Center

10:00am – 10:20am
Fucosylation with Fucosyltransferase VI or Fucosyltransferase VII improves Cord Blood Engraftment
Elizabeth Shpall, MD, MD Anderson Cancer Center
10:20am – 10:40am
Umbilical Cord Blood Stem Cells Cultured in the Presence of Nicotinamide (NiCord®) Provide Long Term Multi-lineage Engraftment
Mitchell Horwitz, MD, Duke University Medical Center

10:40am – 11:00am
Update of Modified Dosing for Inhibition of DPP4 by Sitagliptin to Enhance Single Cord Blood Transplantation in Adult Patients With High Risk Leukemia and Lymphoma
Sherif S. Farag, MD, University of Indiana

11:00am – 11:20am
PGE₂-Modulated Umbilical Cord Transplantation
Corey Cutler, MD, Dana-Farber Cancer Institute

11:20am – 11:40am
Duncan Purtill, MBBS, FRACP, FRCPA, Memorial Sloan-Kettering Cancer Center

11:40am – 12:00pm Discussion

12:00pm-1:00pm Lunch – Pacific Concourse

1:00pm – 3:00pm
Session VIII: New Aspects of Cord Blood Cell Transplantation
Moderators - Jiangiang Li, PhD, Fred Hutchinson Cancer Research Center & Michael Verneris, MD, University of Minnesota

1:00pm – 1:15pm
The Best Abstract Submission:
“Optimizing the Outcomes of Unrelated HLA-Mismatched Cord Blood Transplantation: Predicted Indirectly Recognizable HLA Epitopes - A Possible Novel Donor Selection Tool for Better Disease Control and Reducing the Transplant-Related Toxicity.”
Kirsten A.Thus, MD ̶ University Medical Center, Utrecht

1:15pm – 1:40pm
Antigen Presenting Cell-mediated Expansion of Human Umbilical Cord Blood Yields Long-scale Expansion of Natural Killer Cells with Anti-myeloma Activity
Nina Shah, MD, MD Anderson Cancer Center

1:40pm – 2:00pm
Early NK Cell Proliferation after CB Transplantation is Associated with Superior Disease-Free Survival Due to Reduced Leukemia Relapse
Michael Verneris, MD, University of Minnesota
2:00pm – 2:20pm
Clinical Application and Therapeutic Effect of Fetal Mesenchymal Stem Cells in Prenatal Transplantation
Steven Shaw, MD, MSc, PhD, Chang Gung Memorial Hospital

2:20pm – 2:40pm
Three Kingdoms Saga: Exploring the Mechanism of Graft versus Graft Interactions and Its Influence on Outcomes in Cord Blood Transplant Recipients
Jiangiang Li, PhD, Fred Hutchinson Cancer Research Center

2:40pm – 3:00pm
Experience of Pediatric Stem Cell Transplants in AIIMS, Delhi, India
Sameer Bakhshi, MD, All India Institute of Medical Sciences

3:00pm – 3:20pm Coffee Break – Pacific Concourse

3:20pm – 5:00pm
Session IX: Cord Blood Banking Including Cost Considerations
Moderators – Michael Boo, JD, NMDP & Joanne Kurtzberg, MD, Duke University Medical Center

3:20pm – 3:25pm
Impact of Umbilical Cord Blood Processing on Transplant Outcomes
Karen Ballen, MD, Massachusetts General Hospital

3:35pm – 4:15pm
Costs: The Perspective of a Transplant Physician
Elizabeth Shpall, MD, MD Anderson Cancer Center

3:45pm – 3:55pm
Costs: The Perspective of a Cord Blood Banker
Joanne Kurtzberg, MD, Duke University Medical University

3:55pm – 4:05pm
Cord Blood Banking: Overview of Relative Costs of Cell Source
Michael Boo, JD, NMDP

4:05pm – 4:15pm Discussion

4:15pm – 4:30pm
Navigating Consent Issues in the Collection of Licensed Units: How Should Potential Research Uses be Addressed in the Consent at Collection?
Roberta King, MPH, NMDP

4:30pm – 4:45pm
The Role of Post-Thaw Potency Testing in the Selection of Cord Blood Units
Donna Regan, MT(ASCP)SBB, St. Louis Cord Blood Bank

4:45pm – 5:00pm Discussion
Adjournment Until 2015